This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Scandion Oncology (8VY) Stock Overview

A clinical-stage biotechnology company, develops medicines for the treatment of cancer. More details

8VY fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Has less than 1 year of cash runway

Shares are highly illiquid

Earnings have declined by 16.5% per year over past 5 years

Makes less than USD$1m in revenue (DKK0)

+ 1 more risk

8VY Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW490,896 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

490,896 investors already sharing narratives

View all narratives

Scandion Oncology A/S Competitors

Price History & Performance

Summary of share price highs, lows and changes for Scandion Oncology
Historical stock prices
Current Share Price	€0.0002
52 Week High	€0.0002
52 Week Low	€0.0002
Beta	1.79
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	8VY	DE Biotechs	DE Market
7D	0%	-1.1%	-0.7%
1Y	n/a	11.6%	-0.9%

Return vs Industry: Insufficient data to determine how 8VY performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how 8VY performed against the German Market.

Price Volatility

Is 8VY's price volatile compared to industry and market?
8VY volatility
8VY Average Weekly Movement	n/a
Biotechs Industry Average Movement	7.7%
Market Average Movement	5.4%
10% most volatile stocks in DE Market	12.6%
10% least volatile stocks in DE Market	2.7%

Stable Share Price: 8VY's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine 8VY's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2017	4	Francois Martelet	www.scandiononcology.com

Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV.

Scandion Oncology A/S Fundamentals Summary

How do Scandion Oncology's earnings and revenue compare to its market cap?
8VY fundamental statistics
Market cap	€46.95k
Earnings (TTM)	-€4.91m
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is 8VY overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
8VY income statement (TTM)
Revenue	DKK 0
Cost of Revenue	DKK 0
Gross Profit	DKK 0
Other Expenses	DKK 36.66m
Earnings	-DKK 36.66m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Aug 28, 2025

Earnings per share (EPS)	-0.16
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 8VY perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/07/25 13:18
End of Day Share Price	2025/07/22 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Scandion Oncology A/S is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Soo Romanoff	Edison Investment Research
Christian Binder	Redeye